Literature DB >> 26604250

D-4F Decreases White Matter Damage After Stroke in Mice.

Xu Cui1, Michael Chopp1, Alex Zacharek1, Chengcheng Cui1, Tao Yan1, Ruizhuo Ning1, Jieli Chen2.   

Abstract

BACKGROUND AND
PURPOSE: Stroke-induced neuroinflammation and white matter damage are associated with neurological deficits. Whether D-4F, an apolipoprotein A-I mimetic peptide, treatment of stroke decreases neuroinflammation and white matter damage and improves functional outcome has not been investigated.
METHODS: Adult male C57BL/6 mice were subjected to permanent middle cerebral artery occlusion (MCAo) and were orally administered saline as a vehicle control and different doses of D-4F (2, 4, 8, 16, or 32 mg/kg) starting at 2 h after MCAo and daily until euthanized at 7 days after MCAo. D-4F treatment did not alter the blood levels of high-density lipoprotein, total cholesterol, triglyceride, blood-brain barrier leakage, and infarction volume compared with control group.
RESULTS: D-4F (16 mg/kg) treatment of stroke significantly improved functional outcome, increased the white matter density and the number of oligodendrocyte progenitor cells in the ischemic boundary zone of the ipsilateral striatum, and increased myelin basic protein, insulin-like growth factor-1 (IGF1), but decreased inflammatory factor Toll-like receptor-4 and tumor necrosis factor-α expression in the ischemic brain 7 days after MCAo (P<0.05, n=11/group). The neurite/axonal outgrowth in primary cultured neurons was significantly increased when treated with D-4F (100 ng/mL) and IGF1 (100 ng/mL) compared with the nontreatment control. Inhibition of IGF1 significantly attenuated D-4F or IGF1 treatment-induced axonal outgrowth. D-4F-treatment did not increase oligodendrocyte-progenitor cell proliferation but decreased oligodendrocyte-progenitor cell death.
CONCLUSIONS: D-4F treatment initiated 2 h after MCAo decreases neuroinflammation and white matter damage and improves functional outcome after stroke. D-4F-induced increase in IGF1 may contribute to D-4F-induced neurite/axonal outgrowth after stroke.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  axon; insulin-like growth factor-1; neuroinflammation; stroke; white matter

Mesh:

Substances:

Year:  2015        PMID: 26604250      PMCID: PMC4702511          DOI: 10.1161/STROKEAHA.115.011046

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  38 in total

Review 1.  Regulation of apoptosis by insulin-like growth factor (IGF)-I.

Authors:  Ron Kooijman
Journal:  Cytokine Growth Factor Rev       Date:  2006-04-18       Impact factor: 7.638

Review 2.  Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins.

Authors:  Satoshi Imaizumi; Mohamad Navab; Cecilia Morgantini; Christina Charles-Schoeman; Feng Su; Feng Gao; Murray Kwon; Ekambaram Ganapathy; David Meriwether; Robin Farias-Eisner; Alan M Fogelman; Srinivasa T Reddy
Journal:  Circ J       Date:  2011-05-28       Impact factor: 2.993

3.  Myelin loss associated with neuroinflammation in hypertensive rats.

Authors:  Fakhreya Y Jalal; Yi Yang; Jeffrey Thompson; Anita C Lopez; Gary A Rosenberg
Journal:  Stroke       Date:  2012-02-23       Impact factor: 7.914

4.  Niaspan reduces high-mobility group box 1/receptor for advanced glycation endproducts after stroke in type-1 diabetic rats.

Authors:  X Ye; M Chopp; X Liu; A Zacharek; X Cui; T Yan; C Roberts; J Chen
Journal:  Neuroscience       Date:  2011-06-13       Impact factor: 3.590

5.  White matter integrity and core cognitive function in children diagnosed with sickle cell disease.

Authors:  Nadia Scantlebury; Donald Mabbott; Laura Janzen; Conrad Rockel; Elysa Widjaja; Garland Jones; Melanie Kirby; Isaac Odame
Journal:  J Pediatr Hematol Oncol       Date:  2011-04       Impact factor: 1.289

6.  Expression of the human apolipoprotein A-I gene in transgenic mice alters high density lipoprotein (HDL) particle size distribution and diminishes selective uptake of HDL cholesteryl esters.

Authors:  T Chajek-Shaul; T Hayek; A Walsh; J L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

7.  Tumor necrosis factor-alpha decreases insulin-like growth factor-I messenger ribonucleic acid expression in C2C12 myoblasts via a Jun N-terminal kinase pathway.

Authors:  Robert A Frost; Gerald J Nystrom; Charles H Lang
Journal:  Endocrinology       Date:  2003-05       Impact factor: 4.736

Review 8.  Oligodendrocyte pathophysiology and treatment strategies in cerebral ischemia.

Authors:  Gabriella Mifsud; Christian Zammit; Richard Muscat; Giuseppe Di Giovanni; Mario Valentino
Journal:  CNS Neurosci Ther       Date:  2014-04-07       Impact factor: 5.243

9.  Blood brain barrier and neuroinflammation are critical targets of IGF-1-mediated neuroprotection in stroke for middle-aged female rats.

Authors:  Shameena Bake; Amutha Selvamani; Jessica Cherry; Farida Sohrabji
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

10.  An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration.

Authors:  Xun Chen; Charlotte Burton; Xuelei Song; Lesley McNamara; Annunziata Langella; Simona Cianetti; Ching H Chang; Jun Wang
Journal:  Int J Biol Sci       Date:  2009-07-28       Impact factor: 6.580

View more
  13 in total

Review 1.  Diabetes complications and extracellular vesicle therapy.

Authors:  Setareh Soltani; Kamran Mansouri; Shahram Parvaneh; Avnesh S Thakor; Flemming Pociot; Reza Yarani
Journal:  Rev Endocr Metab Disord       Date:  2021-10-14       Impact factor: 6.514

2.  Insulin-Like Growth Factor, Inflammation, and MRI Markers of Alzheimer's Disease in Predominantly Middle-Aged Adults.

Authors:  Katharina Wittfeld; Mekala R Raman; Sarah C Conner; Asra Aslam; Alexander Teumer; Matthias Nauck; Norbert Hosten; Mohamad Habes; Charles DeCarli; Ramachandran S Vasan; Alexa S Beiser; Jayandra J Himali; Sudha Seshadri; Hans J Grabe; Claudia L Satizabal
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

3.  Axl activation attenuates neuroinflammation by inhibiting the TLR/TRAF/NF-κB pathway after MCAO in rats.

Authors:  Guangyong Wu; Devin W McBride; John H Zhang
Journal:  Neurobiol Dis       Date:  2017-11-28       Impact factor: 5.996

Review 4.  Therapeutic Potential of Cytokines in Demyelinating Lesions After Stroke.

Authors:  Yi-Sha Guo; Mei Yuan; Yu Han; Xin-Ya Shen; Zhen-Kun Gao; Xia Bi
Journal:  J Mol Neurosci       Date:  2021-05-10       Impact factor: 3.444

Review 5.  Assessed and Emerging Biomarkers in Stroke and Training-Mediated Stroke Recovery: State of the Art.

Authors:  Marialuisa Gandolfi; Nicola Smania; Antonio Vella; Alessandro Picelli; Salvatore Chirumbolo
Journal:  Neural Plast       Date:  2017-03-08       Impact factor: 3.599

Review 6.  Potential Medications or Compounds Acting on Toll-like Receptors in Cerebral Ischemia.

Authors:  Man Li; Jing Liu; Ying Bi; Jixiang Chen; Lei Zhao
Journal:  Curr Neuropharmacol       Date:  2018-01-30       Impact factor: 7.363

Review 7.  HDL from an Alzheimer's disease perspective.

Authors:  Emily B Button; Jérôme Robert; Tara M Caffrey; Jianjia Fan; Wenchen Zhao; Cheryl L Wellington
Journal:  Curr Opin Lipidol       Date:  2019-06       Impact factor: 4.776

8.  Human umbilical cord blood cells rescued traumatic brain injury-induced cardiac and neurological deficits.

Authors:  Haotian Hu; Qiang Zhao; Xiaoxuan Liu; Tao Yan
Journal:  Ann Transl Med       Date:  2020-03

9.  ApoA-I Mimetic Peptide Reduces Vascular and White Matter Damage After Stroke in Type-2 Diabetic Mice.

Authors:  Xiaohui Wang; Rongwen Li; Alex Zacharek; Julie Landschoot-Ward; Michael Chopp; Jieli Chen; Xu Cui
Journal:  Front Neurosci       Date:  2019-10-25       Impact factor: 4.677

10.  Administration of Downstream ApoE Attenuates the Adverse Effect of Brain ABCA1 Deficiency on Stroke.

Authors:  Xiaohui Wang; Rongwen Li; Alex Zacharek; Julie Landschoot-Ward; Fengjie Wang; Kuan-Han Hank Wu; Michael Chopp; Jieli Chen; Xu Cui
Journal:  Int J Mol Sci       Date:  2018-10-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.